EASTONBIOPHARMACEUTICALS(SH:688513) Xin Lang Cai Jing·2025-09-09 07:23Group 1 - The stock of Yuandong Biopharmaceuticals fell by 5.01% on September 9, closing at 56.14 CNY per share, with a trading volume of 187 million CNY and a turnover rate of 1.82%, resulting in a total market capitalization of 9.911 billion CNY [1] - Yuandong Biopharmaceuticals, established on June 1, 2009, and listed on September 2, 2020, is based in Chengdu, Sichuan Province. The company's main business involves the research, production, and sales of chemical raw materials and chemical drug formulations [1] - The revenue composition of Yuandong Biopharmaceuticals includes 78.75% from formulation sales, 9.22% from raw material sales, 6.79% from technical services and transfers, 4.01% from CMO/CDMO services, and 1.22% from other sources [1] Group 2 - The Hongde Medical Innovation Mixed Fund A (012481) holds 27,000 shares of Yuandong Biopharmaceuticals, representing 7.84% of the fund's net value, making it the third-largest holding. The estimated floating loss today is approximately 79,900 CNY [2] - The Hongde Medical Innovation Mixed Fund A was established on February 22, 2023, with a latest scale of 10.4748 million CNY. Year-to-date returns are 66.27%, ranking 251 out of 8,179 in its category; the one-year return is 85.28%, ranking 598 out of 7,984; and since inception, the return is 10.87% [2]